#1292ef

Abiomed

#f9f9f9

Michael Minogue

Brett Prince

Mike Howley

Frank Natale

Jason Fore

Kelley Boucher

Patrick Chuinard

Parvin Miah

Dr.thorsten Siess

Michael Tomsicek

Glen Fantuzzi

Raymond Kelley

Dawn Bardot

Greg Olen

John Mone

Ken Ryder

Bill Bolt

James Towne

Amy (amy Narcotta) Grubb

Karen Mahoney

Mike Ambeliotis

About us
Our Story
Our Story
Abiomed was founded in 1981 for the purpose of developing the world's first artificial heart. This interactive timeline shows how Abiomed?s mission evolved to focus on native heart recovery. Through its history, Abiomed has been dedicated to bringing the most advanced and innovative technology to patients and physicians.
2022
Abiomed acquired by Johnson & Johnson
Abiomed surpasses 250,000 patients treated with Impella?
U.S. FDA grants 510(k) clearance for Impella Low Profile Sheath
Physicians treat the first patient in the world with Impella BTR?
All post-approval studies for Impella heart pumps completed successfully
Physicians treat first patient Impella 5.5? in Japan
2021
First patient enrolls in the PROTECT IV randomized controlled trial
Abiomed surpasses 200,000 patients treated with Impella
U.S. FDA grants breakthrough device designation to Impella ECP?, the world?s smallest heart pump
U.S. FDA grants the highest level of approval to the Impella RP? with SmartAssist? for right heart failure
Abiomed acquires preCARDIA to improve outcomes for heart failure patients
2020
Abiomed acquires Breethe? and its OXY-1 System and treats first patients with ECMO technology above left
Physicians treat first patients with the 9 French Impella ECP above right
Abiomed surpasses 150,000 patients treated with Impella
U.S. FDA grants EUA for Impella to provide therapy to certain COVID-19 patients
U.S. FDA approves data streaming from the Impella console, setting the stage for artificial intelligence (AI) algorithms
2019
First U.S. patients are treated with Impella 5.5 with SmartAssist
1,000th patient treated with Impella in Japan
First patient enrolls in STEMI DTU? pivotal randomized controlled trial
2018
Abiomed surpasses 100,000 patients treated with Impella
German physicians treat first patient with Impella 5.5 with SmartAssist
SmartAssist technology receives regulatory approval
Abiomed launches Women's Initiative for Heart Recovery
U.S. FDA grants approval for expanded indications for Impella
Investigators announce successful STEMI DTU pilot randomized controlled trial results
2017
Abiomed celebrates the grand opening of its newly-expanded headquarters in Danvers, MA
Abiomed surpasses 50,000 patients treated with Impella
First patient enrolls in STEMI DTU pilot randomized controlled trial
U.S. FDA grants PMA approval for Impella RP for right heart failure
Physicians treat first patient with Impella in Japan
2016
Entire family of Abiomed Impella left side heart pumps receive U.S. FDA PMA approval to enable heart recovery in cardiogenic shock
The Impella 2.5? and Impella 5.0? heart pumps receive regulatory approval in Japan
U.S. FDA grants expanded PMA approval to Impella CP? for high-risk PCI procedures
2015
U.S. FDA grants PMA approval to Impella 2.5 for elective and urgent high-risk procedures
2014
Abiomed announces the acquisition of ECP, a medical device company based in Berlin, Germany
Abiomed surpasses 20,000 patients supported with Impella
2013
RECOVER RIGHT clinical trial begins in the U.S. for the Impella RP heart pump
2012
PROTECT II randomized controlled trial outcomes publish in Circulation, the journal of the American Heart Association
Impella CP heart pump receives U.S. FDA 510(k) clearance
Abiomed cofounds MedTechVets to help military veterans find jobs in the medical device industry
2011
New Automated Impella Controller? (AIC) is available
Abiomed achieves non-GAAP profitability
RECOVER I clinical trial outcomes publish in the Journal of Thoracic and Cardiovascular Surgery
2009
AB Portable Driver receives U.S. FDA approval and first patient is discharged on AB5000?
Impella 5.0? and Impella LD? heart pumps receive U.S. FDA 510(k) clearance
2008
Impella 2.5 heart pump receives U.S. FDA 510(k) clearance
Abiomed completes PROTECT I clinical trial
2005
Abiomed acquires Impella CardioSystems in Aachen, Germany
2004
Under new CEO, Mike Minogue, Abiomed transitions to heart recovery focus
AB5000? receives U.S. FDA approval for bridge-to-recovery
2001
Physicians treat first AbioCor patient with the first totally implantable artificial heart
1992
BVS 5000? becomes the first ventricular assist device ever U.S. FDA-approved for bridge-to-recovery
1991
Abiomed celebrates 10th anniversary
1987
Abiomed begins trading on NASDAQ under ABMD; $1.5M revenue first year close
 
1981
Abiomed is founded to develop the first artificial heart
NPS-124

A little over two weeks later, Dr. Eladasari was discharged home with his native heart and normal heart function.